Zhu B, Fu Y
Guangzhou First People's Hospital.
Zhonghua Fu Chan Ke Za Zhi. 1996 Dec;31(12):721-3.
To investigate the treatment of preterm labor with the beta-adrenergic agonist ritodrine.
126 women with preterm labor were randomly assigned to intravenous infusion of ritodrine or magnesium sulfate treatment. Using minimal effective dosage for inhibition of uterine activity, terminating therapy on time, and repeating the i.v. infusion if contraction restarted were the strategy for treatment.
Ritodrine was significantly more effective both in the treating period for suppression of contraction (2.33 +/- 0.63 hr for initiation of inhibiting uterine activity, 9.38 +/- 3.88 days of accumulative treating period) and prolongation of gestation (4.81 +/- 2.83 wks) than that of the magnesium sulfate (P < 0.001, 0.005 and 0.01 respectively), and had a term labor of 73.44%. There was no serious cardiac and pulmonary complications in the ritodrine group.
The present study has shown that ritodrine as a tocolytic agent is highly effective for the management of preterm labor and relative safe for mother and fetus.
探讨β-肾上腺素能激动剂利托君治疗早产的效果。
将126例早产孕妇随机分为两组,分别静脉输注利托君或硫酸镁进行治疗。采用抑制子宫活动的最小有效剂量,按时终止治疗,宫缩重新出现时重复静脉输注作为治疗策略。
在抑制宫缩的治疗期(抑制子宫活动开始时间为2.33±0.63小时,累计治疗期为9.38±3.88天)以及延长孕周方面(4.81±2.83周),利托君均显著优于硫酸镁(P分别<0.001、0.005和0.01),足月分娩率为73.44%。利托君组未出现严重心肺并发症。
本研究表明,利托君作为一种宫缩抑制剂,对早产的治疗效果显著,对母婴相对安全。